Alkem Laboratories Ltd Upgraded to Hold by MarketsMOJO on Technical and Valuation Improvements

Quality Assessment: Mixed Signals Amid Financial Challenges

Alkem Laboratories continues to demonstrate strong management efficiency, with a return on equity (ROE) of 17.48% and a return on capital employed (ROCE) of 19.58%, underscoring effective utilisation of shareholder funds. The company remains net-debt free, a significant positive in the capital-intensive pharmaceutical sector, providing financial flexibility. However, recent quarterly results for Q4 FY25-26 revealed a negative financial performance, with operating profit growth slowing to an annualised rate of 9.33% over the past five years. Additionally, the operating profit to interest coverage ratio dropped to a low of 9.60 times, while interest expenses rose to ₹53.88 crores, signalling increased financial strain.

Non-operating income accounted for 35.87% of profit before tax (PBT) in the latest quarter, indicating reliance on ancillary income streams rather than core operations. Furthermore, promoter confidence appears to be waning, with a 1.5% reduction in promoter stake over the previous quarter, now standing at 49.7%. This decrease may reflect concerns about future growth prospects or strategic direction.

Valuation: Shift from Attractive to Fair

The valuation grade for Alkem Laboratories has been downgraded from attractive to fair, reflecting a re-rating in line with the company’s current price multiples. The stock trades at a price-to-earnings (PE) ratio of 27.99, which is higher than some peers such as Zydus Lifesciences (PE 21.06) and Lupin (PE 19.66), but lower than more expensive names like Mankind Pharma (PE 52.48) and Laurus Labs (PE 94.9). The price-to-book value stands at 4.89, indicating a premium over book value but still within reasonable bounds for a mid-cap pharmaceutical firm.

Enterprise value to EBITDA (EV/EBITDA) is 22.35, suggesting the stock is fairly valued relative to earnings before interest, tax, depreciation and amortisation. The PEG ratio of 2.43 points to moderate growth expectations priced into the stock, higher than some peers but justified by Alkem’s consistent market-beating returns. Dividend yield remains modest at 0.90%, reflecting a focus on reinvestment rather than income distribution.

Financial Trend: Market-Beating Returns Despite Profitability Concerns

Alkem Laboratories has delivered robust returns relative to the broader market. Over the past year, the stock generated a 13.10% return compared to the Sensex’s decline of 4.95%. Year-to-date, the stock is up 2.75% while the Sensex has fallen 8.81%. Longer-term performance is even more impressive, with a 10-year return of 268.60% versus the Sensex’s 178.37%, and a five-year return of 66.60% compared to 48.87% for the benchmark.

However, the company’s operating profit growth has been subdued, with an annualised increase of just 9.33% over five years. The recent quarterly results showed a decline in operating profit and increased interest costs, which may weigh on near-term earnings momentum. Despite these challenges, Alkem’s high management efficiency and net-debt free status provide a cushion against volatility.

Technicals: Upgrade to Mildly Bullish Outlook

The technical grade for Alkem Laboratories has improved significantly, shifting from a sideways trend to a mildly bullish stance. Key weekly indicators such as MACD and Bollinger Bands are bullish, while monthly MACD remains mildly bearish, reflecting some caution in the longer term. The KST (Know Sure Thing) indicator is bullish on both weekly and monthly charts, supporting the positive momentum.

Relative Strength Index (RSI) shows no clear signal on weekly or monthly timeframes, suggesting the stock is not overbought or oversold. Moving averages on the daily chart are mildly bearish, indicating some short-term consolidation. Dow Theory analysis reveals no clear weekly trend but a mildly bearish monthly outlook. On-balance volume (OBV) is neutral weekly but mildly bullish monthly, signalling cautious accumulation by investors.

Price action supports this technical upgrade, with the stock closing at ₹5,656.55 on 21 Jul 2026, up 1.87% from the previous close of ₹5,552.90. The 52-week high stands at ₹5,933.00 and the low at ₹4,740.65, with the current price near the upper end of this range, reflecting renewed investor interest.

Comparative Industry Position and Outlook

Within the Pharmaceuticals & Biotechnology sector, Alkem Laboratories holds a mid-cap status and a Mojo Grade of Hold, reflecting a balanced risk-reward profile. Its valuation metrics place it in the fair category, contrasting with peers such as Zydus Lifesciences and Lupin, which remain attractively valued, and others like Mankind Pharma and Laurus Labs, which are considered expensive or very expensive.

The company’s consistent outperformance relative to the Sensex and BSE500 indices over multiple time horizons highlights its resilience and market positioning. However, the recent negative quarterly financials and promoter stake reduction introduce caution. Investors should weigh these factors carefully, considering the company’s strong technical momentum and fair valuation against the backdrop of subdued profit growth and rising interest costs.

Conclusion: A Cautious Hold with Potential Upside

Alkem Laboratories’ upgrade from Sell to Hold is driven primarily by improved technical indicators and a fairer valuation relative to its historical multiples and peers. While the company faces challenges in profitability and promoter confidence, its strong management efficiency, net-debt free balance sheet, and market-beating returns provide a solid foundation. The mildly bullish technical outlook suggests potential for further price appreciation, but investors should remain vigilant regarding quarterly earnings trends and sector dynamics.

Overall, the Hold rating reflects a balanced view that acknowledges both the strengths and risks inherent in Alkem Laboratories’ current position, making it a stock to watch for investors seeking exposure to the pharmaceuticals sector with moderate risk tolerance.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today